The subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis

Basit Öğe Kaydı
dc.contributor.authorTunik, Selcuk
dc.contributor.authorNergiz, Yusuf
dc.contributor.authorKeklikci, Ugur
dc.contributor.authorAkkus, Murat
dc.date.accessioned2024-04-24T16:01:53Z
dc.date.available2024-04-24T16:01:53Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractTo investigate the effects of cetuximab and bevacizumab on experimental rat model of corneal angiogenesis. The right eyes of 28 male Sprague-Dawley rats were included in silver nitrate cauterization-induced corneal angiogenesis model. They were divided into four groups: (1) silver nitrate cauterization-induced and 0.15 ml serum physiologic was given to the angiogenesis group, (2) bevacizumab was given 1.25 mg to the bevacizumab group, (3) cetuximab was given 5 mg to the cetuximab group, and (4) 1.25 mg bevacizumab plus 5 mg cetuximab were given to the bevacizumab + cetuximab group. All eyes were exposed to the treatment on days 1, 4, and 7 of the experiment, and drugs were given subconjunctivally. The left eyes were untreated and used as sham. On day 8, the treated eyes were evaluated biomicroscopically. Then, the rats were sacrificed, and corneal specimens were prepared for histopathologic examinations. The degree of angiogenesis inhibition was observed as 50.8 % in bevacizumab, 54.3 % in cetuximab, and 15.8 % in bevacizumab + cetuximab groups by biomicroscopic evaluation. According to the histopathological and immunohistochemical findings obtained from the present study, the amount of angiogenesis was determined to have decreased considerably in both the bevacizumab and cetuximab groups; also, relatively less inhibiton was observed in the bevacizumab + cetuximab group. Subconjunctival injection of cetuximab and bevacizumab is effective in reducing corneal angiogenesis in silver nitrate cauterization induced angiogenesis model of rats. Further investigation is needed to assess the potential side-effects of the drugs, especially cetuximab.en_US
dc.description.sponsorshipDicle Universityen_US
dc.description.sponsorshipThis study was supported by Scientific Research Fund of Dicle University. The authors have no financial interest in any of the products mentioned in the manuscript. We would like to thank English Lecturer Ibrahim Tunik for his checking the manuscript in terms of its grammar and spelling errors.en_US
dc.identifier.doi10.1007/s00417-012-2008-6
dc.identifier.endpage1167en_US
dc.identifier.issn0721-832X
dc.identifier.issue8en_US
dc.identifier.pmid22527313
dc.identifier.scopus2-s2.0-84866414453
dc.identifier.scopusqualityQ1
dc.identifier.startpage1161en_US
dc.identifier.urihttps://doi.org/10.1007/s00417-012-2008-6
dc.identifier.urihttps://hdl.handle.net/11468/14459
dc.identifier.volume250en_US
dc.identifier.wosWOS:000306791700006
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofGraefes Archive For Clinical and Experimental Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCetuximaben_US
dc.subjectBevacizumaben_US
dc.subjectCorneal Angiogenesisen_US
dc.subjectRaten_US
dc.titleThe subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesisen_US
dc.titleThe subconjunctival use of cetuximab and bevacizumab in inhibition of corneal angiogenesis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu